Browse the evidence

Elevated Remnant Cholesterol Inflammatory Index (RCII) is independently associated with a significantly higher risk of incident cardiovascular disease (CVD), including heart disease and stroke.

If you are over 45, ask your doctor about your Remnant Cholesterol Inflammatory Index (RCII). It combines your cholesterol levels with inflammation markers to better predict heart disease risk than weight or BMI alone. High RCII indicates a need for targeted lifestyle interventions focusing on both lipid management and inflammation reduction.

RCII partially mediates the association between ABSI and incident CVD, with the mediation proportion increasing across higher ABSI quartiles.

Understanding that inflammation and lipid metabolism (RCII) play a role in how abdominal fat (ABSI) affects heart health can guide more targeted treatments. For those with high ABSI, addressing inflammation may provide additional cardiovascular protection beyond just weight management.

Moderate to severe weight change (loss or gain) of ≥5% within a 2-year interval is associated with a significantly increased risk of suicide mortality, exhibiting a reverse J-shaped curve.

If you experience rapid, unintentional weight loss or gain (≥5% in 2 years), it is a significant physiological stress signal. While weight loss is often pursued for health, rapid changes—especially if unexplained by diet/exercise—warrant medical and psychological evaluation to rule out underlying conditions or mental health risks, rather than simply viewing the change as a success or failure.

The Obesity Lifecycle Model demonstrates favorable concordance with observed clinical and quality-of-life outcomes, validating its use for evaluating obesity-related complications and informing healthcare decision making.

Healthcare decision-makers can use the Obesity Lifecycle Model to assess the cost-effectiveness of obesity therapies with confidence, as it has been validated to accurately predict clinical complications and quality-of-life impacts.

Adipose tissue (AT) dysfunction, rather than fat mass alone, is the primary mechanistic link between obesity and adverse health outcomes, explaining why some individuals with obesity remain metabolically healthy while others with normal weight develop obesity-related diseases.

Your health risk from obesity is not just about how much you weigh, but how your fat tissue is functioning. Factors like visceral fat, inflammation, and insulin sensitivity matter more than BMI alone. Focus on metabolic health markers rather than just the scale.

Obesity accelerates biological cardiovascular ageing by inducing structural and functional cardiac and vascular changes that mimic those of chronological ageing, independent of traditional risk factors.

Your heart ages based on how you treat it, not just your birth year. Obesity forces your heart to work harder and remodels it to look and function like an older, non-obese heart. Losing weight can reverse these changes, effectively turning back the biological clock of your cardiovascular system.

Leptin therapy is effective for weight loss only in patients with leptin deficiency (low circulating levels), not in those with leptin resistance (high levels).

Leptin injections are only effective for people with a specific genetic deficiency causing low leptin levels. For most people with obesity, leptin levels are high, and leptin injections do not work.

Bariatric surgery is a highly effective therapeutic option for individuals with severe obesity (BMI ≥40 or ≥35 with comorbidities) that induces T2DM remission through metabolic changes beyond simple restriction.

If you have a BMI of 40 or higher (or 35+ with diabetes/liver disease), consult a specialist about bariatric surgery. It is a proven, durable treatment that can reverse diabetes through hormonal changes, not just weight loss, but requires lifelong medical monitoring.

Resmetirom, a selective thyroid hormone receptor beta (THR-β) agonist, significantly reduces hepatic fat content and improves fibrosis markers in patients with non-cirrhotic MASH.

If you have MASH (formerly NASH) with significant liver fat, ask your doctor about resmetirom. It is an FDA-approved medication that targets the liver specifically to reduce fat and improve fibrosis. The standard dose is 80mg or 100mg taken once daily. It is not a supplement but a prescription drug with specific eligibility criteria (non-cirrhotic MASH).

Chronic administration of GIP receptor agonists (specifically GIP108) causes functional desensitization of the GIP receptor in pancreatic islets, reducing the efficacy of subsequent glucose-lowering challenges.

Long-term use of GIP-based therapies (like tirzepatide) triggers a biological adaptation where the pancreas becomes less responsive to the drug's glucose-lowering signal. This is a known mechanism called desensitization. However, the drug still promotes weight loss, suggesting the benefit comes from multiple pathways, not just pancreatic sensitivity. If glycemic control wanes, dose adjustments may be necessary.

Cardiac diastolic function, specifically the E/e' ratio and Left Atrial Volume Index (LAVI), significantly moderates the reduction in relative peak oxygen uptake in Type 2 Diabetes patients.

For T2D patients, standard cardiac checks might miss the root cause of exercise intolerance. If you struggle with exercise despite normal ejection fraction, ask about diastolic function (E/e' ratio). Addressing this through specific training (like high-intensity interval training, as suggested by the authors) may be more effective than generic advice.

GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.

If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.

SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.

SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.

If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.

Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.

If you have MASH with advanced fibrosis but no cirrhosis, ask your doctor about resmetirom. It is an approved treatment that has been shown to improve both steatohepatitis and fibrosis with a favorable safety profile.

Bariatric surgery significantly reduces the risk of developing heart failure and improves mortality in patients with existing heart failure and obesity.

For severe obesity, bariatric surgery is a highly effective treatment that can prevent heart failure and significantly improve survival in those who already have it. It is safe and can even be used as a bridge to heart transplantation in severe cases. Consult with a bariatric surgeon and cardiologist to see if you are a candidate.

GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.

If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.

The reduction in schizophrenia risk associated with GLP-1 receptor agonists is mediated by body mass index (BMI) rather than glycemic control.

The mental health benefits of GLP-1 drugs for schizophrenia risk appear to come from weight loss, not from lowering blood sugar. This means that interventions focusing on weight management (whether through GLP-1 drugs or other means) may be the key to reducing this specific psychiatric risk. It highlights the importance of addressing obesity in mental health prevention strategies.

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

Body weight stigma acts as a significant barrier to healthcare engagement and long-term weight management success.

If you feel judged by healthcare providers, it is a common and valid experience that can hinder your care. Seek out providers who practice weight-inclusive or stigma-informed care. Addressing the psychological burden of stigma is a crucial part of effective obesity management.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) cause dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) primarily during dose escalation, leading to discontinuation in 3-17% of non-diabetic users.

If you are using a GLP-1 medication like semaglutide or tirzepatide, expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These symptoms are common but usually mild and transient. To manage them, follow a slow titration schedule, eat smaller, low-fat meals, and stay hydrated. Most people adapt over time, but if side effects are severe, consult your doctor about adjusting the dose.

Intermittent Hypoxia (IH) is a key pathogenic factor in OSA that drives cardiovascular and metabolic disease through vascular remodelling, atherosclerosis, and insulin resistance, independent of obesity.

The repeated drops in oxygen during sleep (Intermittent Hypoxia) are what actually damage your heart and metabolism, not just the breathing stops themselves. Managing OSA is crucial to prevent this cycle of damage.

Overweight status (BMI 25-<30) is not associated with increased risk for most cardiovascular outcomes and may have a neutral or slightly protective effect on all-cause mortality compared to normal weight.

Being overweight is not as strongly linked to heart disease or death as obesity. While weight management is still beneficial, the urgency is lower for overweight individuals compared to those with obesity. Focus on overall health metrics rather than just weight.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide induce significant lean mass loss (muscle wasting) alongside fat mass loss, which exacerbates sarcopenia and frailty in patients with advanced heart failure.

If you have heart failure and are using GLP-1RAs (like Ozempic or Wegovy), be aware that you will likely lose muscle along with fat. To protect your strength, prioritize high-protein foods and engage in resistance exercise regularly. Discuss these risks with your doctor to balance heart benefits against muscle loss.